Clinical trials
catalyst calendar across sponsors →Studies where KPRX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
5 interventional · 1 with posted results
Held by 5 tracked-famous managers (CITADEL ADVISORS LLC, TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC) · FINRA short interest 1.0 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis PigmentosaNCT06628947To assess the safety and tolerability of multiple doses of KIO-301 administered by IVT injection bilaterally of KIO-301 in patients with late-stage RP.Randomized · Quadruple-masked · Treatment | Phase 2 | Recruiting | Other: Placebo (Sterile Saline or Balanced Salt Solution) · Drug: 100 μg KIO-301, 50 μg KIO-301 | Retinitis Pigmentosa | 36 | Aug 2027 | ≤ 377 d | 2026-06-18 |
| Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular EdemaNCT06825702Safety and TolerabilityNon-randomized · Open-label · Treatment | Phase 2 | Recruiting | Drug: KIO-104 | Macular Edema | 28 | Nov 2026 | ≤ 103 d | 2026-06-16 |
| A Multi-Centre, Randomised, Controlled, Masked Phase 2 Study of the Safety and Efficacy of KIO-101 Ophthalmic Solution, Versus Vehicle Control in the Treatment of Dry Eye Disease in Patients With Autoimmune DiseaseNCT05629364Change in Schirmer's 1 testRandomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Study halted prematurely but potentially will resume | Drug: KIO-101 | Dry Eye Disease | 4 | 2024-01-09actual | — | 2024-01-10 |
| A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)NCT05282953Main Study Primary Outcome MeasureOpen-label · Treatment | Phase 1/2 | Completed | Drug: KIO-301 | Retinitis Pigmentosa, Choroideremia, Non-Syndromic Rod-Dominant Inherited Retinal Diseases | 32 | 2023-08-10actual | — | 2026-05-04 |
| A Study of the KIO-201 (Ocular Bandage Gel) for Improving Persistent Corneal Epithelial DefectsNCT05436288results2024-04-03Percentage of Patients Achieving Corneal Healing (<0.5 mm2 Lesion Size) of the Persistent Corneal Epithelial Defect at 4 WeeksOpen-label · TreatmentStudy Protocol ↗ | Phase 2 | Completed | Drug: KIO-201, a Crosslinked Thiolated Carboxymethyl Hyaluronic Acid 0.75% (CMHA-S) | Persistent Corneal Epithelial Defect | 10 | 2022-12-22actual | — | 2024-04-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19